Full-Time
Pharmaceutical Sales Specialist Primary Care
Updated on 7/22/2026
AstraZeneca
10,001+ employees
Global pharmaceutical company developing prescription medicines
Compensation Overview
$80k - $182k/yr
San Bernardino, CA, USA
In Person
 Medical, Clinical & Veterinary (1) |
|---|
 Sales & Account Management (1) |
|---|
Get referred to AstraZeneca
Find people who can refer or advise you
- Bachelor’s Degree
- 0 - 2+ years of demonstrated Sales or B2B, or Commercial experience
- A valid driver’s license and safe driving record
- Customer Focus: Strong customer relationship management skills with the ability to understand and address customer needs
- Business Acumen: Ability to analyze and interpret complex data to develop strategic sales plans
- Technical Aptitude: Proficiency in using digital tools and platforms to engage with healthcare professionals
- Adaptability: Flexibility and adaptability to changing market conditions and customer needs
- Collaborative: Ability to work effectively in a team environment and collaborate with cross-functional teams
- Develop and demonstrate knowledge of clinical disease states and treatment guidelines
- Effectively communicate product information to healthcare professionals
- Execute call plans and Brand Strategy by translating data to actionable insights
- Adapt to and demonstrate a thorough understanding of AZ Selling Model
- Analyze data and trends to build insightful and actionable business plans for your assigned sales territory
- Build relationships and credibility with Primary Care healthcare professionals to effectively position products by establishing unmet needs, clinical differentiation, and fair balance of our Brands
- Leverage multiple channels including digital platforms and face-to-face engagements to drive meaningful customer interactions
- Open to receiving guidance and seek insights for growth and development
- Experience selling to general practitioners (GPs) and primary care centers
- In-depth understanding of the healthcare industry and primary care operations
AstraZeneca develops and markets prescription medicines and vaccines for global health, focusing on oncology, cardiovascular/metabolic, respiratory, and infectious diseases. Its products work by targeting specific biological pathways or cells to treat diseases or prevent infections, using small-molecule drugs, biologics, and vaccines. The company differentiates itself through its dual heritage from Sweden and the UK, a broad pipeline, and strong R&D with collaborations to move from discovery to patient access across multiple therapeutic areas. Its goal is to improve people’s health by discovering, developing, and delivering medicines and vaccines worldwide.
Company Size
10,001+
Company Stage
IPO
Headquarters
Cambridge, United Kingdom
Founded
1913
Get referred to AstraZeneca
Find people who can refer or advise you
Simplify's Take
What believers are saying
- Zegfrovy adds $83.4M revenue with 85% growth and first-line potential.
- TQC3721 respiratory deal expands COPD pipeline with up to $1.9B value.
- Rare Disease Centre of Excellence in Abu Dhabi accelerates regional diagnostics.
What critics are saying
- Wainua ATTR-CM Phase III failure blocks $2B+ revenue and cedes market.
- Zegfrovy severe lung disease risk threatens first-line label and reimbursement.
- TQC3721 China Phase III failure could trigger $1.9B milestone clawback.
What makes AstraZeneca unique
- Dual UK-Sweden heritage unifies deep R&D with global commercial scale.
- Leading EGFR-mutated lung cancer franchise anchored by Tagrisso dominance.
- First oral chemo-free monotherapy for EGFR exon 20 via Zegfrovy licensing.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Flexible Work Hours
Growth & Insights and Company News
6 month growth
↑ 3%1 year growth
↑ 3%2 year growth
↑ 6%Weiguo Zhai settles SEC insider trading charges over Icosavax stock. Weiguo Zhai, a former senior director at AstraZeneca Pharmaceuticals, has agreed to settle SEC insider trading charges related to trading in Icosavax Inc. stock ahead of the company's acquisition by AstraZeneca. The SEC filed the settled complaint on July 8, 2026, in the District of Maryland, alleging Zhai misappropriated confidential information and realized $10,006 in illicit profits. What happened. The SEC charged Zhai with violating Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, the antifraud provisions that prohibit trading on material nonpublic information. The commission also charged him with violating Section 14(e) and Rule 14e-3, which specifically address trading in the context of tender offers. The complaint alleged that Zhai was on AstraZeneca's due diligence team evaluating the anticipated acquisition of Icosavax Inc. through a tender offer. He allegedly misappropriated confidential information about the planned transaction and traded on that nonpublic information for personal benefit. Key facts. | Item | Details | | Defendant | Weiguo Zhai, age 56, Potomac, MD | | Employer | AstraZeneca Pharmaceuticals LP | | Target company | Icosavax Inc. | | Shares purchased (own account) | 1,000 shares at $11.04 | | Shares purchased (wife's account) | 1,000 shares at $10.54 | | Illicit profits | $10,006 | | Disgorgement | $10,006 | | Prejudgment interest | $1,535 | | Civil penalty | $10,006 | | Total settlement | $21,547 | | Stock price increase post-announcement | 49.48% | Icosavax impact. Zhai worked at AstraZeneca Pharmaceuticals LP, a wholly owned subsidiary of AstraZeneca PLC, from July 2020 to May 2024. He was based in the Gaithersburg, Maryland office and served as a senior director for research and development. The SEC said Zhai was assigned to AstraZeneca's due diligence team evaluating the anticipated acquisition of Icosavax, a biopharmaceutical company focused on vaccine development. The acquisition was announced on December 12, 2023, with a reported deal value of approximately $800 million. According to the complaint, Zhai purchased 1,000 shares of Icosavax in his own brokerage account at $11.04 per share and another 1,000 shares in his wife's account at $10.54 per share. After the acquisition announcement caused Icosavax stock to rise approximately 49.48%, Zhai sold the shares on December 12 and 13, 2023, realizing aggregate illicit profits of $10,006. What investors should do. Insider trading undermines market integrity and harms ordinary investors who trade without access to material nonpublic information. The SEC's charges against Zhai illustrate how employees with access to confidential deal information can exploit that advantage for personal gain. The SEC emphasized that Zhai consented to the entry of a final judgment permanently enjoining him from future violations of the charged provisions. The settlement is subject to court approval and was reached without Zhai admitting or denying the allegations. How to recover your losses. Investors who traded Icosavax stock during the relevant period may wish to review their account records for potential claims. While the SEC's enforcement action addresses the illegal trading itself, private securities litigation and FINRA arbitration may provide avenues for affected investors to seek compensation. Documenting the timing of trades, the prices paid, and any information known at the time of trading is essential for evaluating potential recovery options. Investors should consult a qualified securities attorney to assess their specific circumstances. Haselkorn & Thibaut fights for investor recovery. Haselkorn & Thibaut is a securities law firm founded by former Wall Street defense attorneys who shifted their practice to represent investors. The firm has recovered over $520 million for clients in securities matters and maintains a 98 percent success rate in resolved nontraded REIT cases. Attorneys are AV Preeminent rated through Martindale-Hubbell, designated as Super Lawyers, and hold a 5.0-star client review average. The firm operates on a contingency basis - no recovery, no fee. Contact haselkorn & Thibaut today. Time matters in recovery cases. The earlier you act, the stronger your position. The firm offers a free case evaluation to assess your losses, review your account history, and explain your options under arbitration or settlement. Offices in Florida, New York, Arizona, Texas, and North Carolina. Former Wall Street defense attorneys with 95+ years of combined experience. No recovery, no fee. This article is for informational purposes only and does not constitute legal advice. Investors should consult a qualified securities attorney to discuss their specific situation. AlphaBetaStock.com is a news and market research website. Its team provides commentary and analysis on a wide range of investment news topics, they have over 20 years of combined financial industry experience and a broad range of educational backgrounds and advanced degrees from around the globe.
Brian Cox returns to Oldham for science education event. If there's one person who can encourage young people in Oldham to study science, it's Professor Brian Cox. The Chadderton-born physicist and broadcaster was back in his home town on Monday, meeting with school pupils and launching a new partnership helping to bring more science opportunities to local primary schools. He joined a panel discussion at the event centre at Boundary Park, where Oldham Athletic Community Trust announced their plans to team up with leading biopharmaceutical company AstraZeneca for the Active Science in Schools Project. Professor Brian Cox joins a panel discussion at Boundary Park event centre (Image: The Oldham Times) Professor Cox was joined by the Greater Science Share founder Dr Lynne Bianchi, AstraZeneca UK chairman Shaun Grady, Oldham Council's director of growth James Kington, and Oldham Athletic Community Trust CEO Sandy Mitchell. The event was co-hosted by Latics CEO Darren Royle. Ahead of the panel discussion, Professor Cox spent the afternoon with primary school pupils, who got a chance to ask the physicist some of their most pressing science questions. He said that there was "no shortage of talent" in Oldham and remarked on how impressed he was by their curiosity and degree-level questions, even encouraging some of them to apply for his University of Manchester courses in the future. Professor Brian Cox said there is "no shortage of talent" in Oldham (Image: The Oldham Times) Speaking in support of the Active Science in Schools Project rollout in Oldham, he added: "You have a place here which is well connected. You look out there and there's the motorway, there's the railway. It's very close to Manchester and the big universities there. "But you also have this untapped potential: you have space, you have development sites. You've got these incredibly talented, curious young people waiting to do wonderful things. "It seems to me that the foundations are here, the raw materials are here. And, as you said, it therefore makes sense to invest." When it comes to inspiring young people to take up STEM subjects, he said it was his hometown Oldham that helped foster his interest in astronomy. As a child, he would head to Chadderton Heights, where night skies are darker and further away from city lights. He added: "That's a real resource. I don't think my imagination would have been captured by astronomy if I'd grown up in a city centre, but I grew up in Chadderton, which is close enough to the night sky." Mayor Pam Byrne joins the panellists for a photo. (Image: The Oldham Times) What is the Active Science in Schools Project? Mr Mitchell explained to the crowd that the Active Science project, organised through the AstraZeneca Partnership, is a six-week programme that will be delivered in Oldham primary schools starting the next academic year. He said: "For us, it's about addressing a need within Oldham schools. How can we enhance what's already going on? "There's some fantastic work already happening, but how can this programme help to enhance that work and reach some of those young people who maybe aren't quite getting the opportunities we'd like them to have in Oldham?" Mr Kington hopes that by leading more young people towards science subjects, it will help "keep Oldham talent in Oldham". He said: "It's just about giving the best for the young people involved. And the better and more skilled our workforce is, the better our businesses will do. "The better our workforce and businesses do, the more jobs will come to Oldham, because people will look for that skilled workforce."
Zymeworks to buy Theravance for $929 million in push to expand beyond cancer. By Thomson Reuters Jun 29, 2026 | 6:13 AM June 29 (Reuters) - Zymeworks said on Monday it will acquire Theravance Biopharma for $929 million in cash, marking the oncology-focused drugmaker's entry into the highly competitive respiratory disease segment. The deal gives Zymeworks access to Theravance's FDA-approved drug Yupelri, a once-daily nebulized treatment for chronic obstructive pulmonary disease (COPD), putting it in competition with major drugmakers that dominate the segment, including GSK, AstraZeneca and Boehringer Ingelheim. COPD is a progressive lung disease that obstructs airflow and makes breathing difficult. Under the agreement, Zymeworks will buy all outstanding Theravance shares for $17 each, implying an about 3.6% discount to the stock's last close on Friday. Zymeworks said Theravance has a 35% net profit share in Yupelri in the U.S., which is marketed in the country through a collaboration with Viatris. In 2025, Yupelri's U.S. net sales were $266.6 million, up 12% from 2024. U.S. net sales rose 7% to $62.4 million in the first quarter of 2026. The acquisition is expected to provide near-term cash flow following the deal's close, which is expected in the second half of 2026, Zymeworks said. Theravance had said earlier this year it was exploring strategic alternatives, including a potential sale, after its experimental drug ampreloxetine for a rare disorder failed a late-stage trial, prompting a restructuring that could affect about half of its workforce. Zymeworks said it will consider monetizing acquired assets, including ampreloxetine, with any proceeds from a potential ampreloxetine deal to be split 20% for Zymeworks and 80% for Theravance shareholders. (Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Jonathan Ananda)
AstraZeneca, Quezon City LGU launch community COPD Screening Program. Jun 19, 2026 - 8List Editor Chronic obstructive pulmonary disease (COPD) is the seventh leading cause of death in the Philippines, with an estimated one in 10 Filipinos aged 40 and above living with the disease. Despite its prevalence, many cases remain undiagnosed until symptoms have already worsened. To help address this challenge, AstraZeneca Philippines and the Quezon City Government have signed a Memorandum of Agreement (MOA) formally launching the Juan Healthy Lung COPD Screening Program in the city. Quezon City teams up with AstraZeneca. This public-private initiative aims to expand risk assessment, healthcare worker education and disease awareness across Quezon City to address the significant underdiagnosis of COPD. "COPD is a growing health challenge. Many Filipinos are often diagnosed late when symptoms have already begun to affect their lives," said Lotis Ramin, Country President, AstraZeneca Philippines. "At AstraZeneca, we have a bold ambition to transform how chronic respiratory diseases are detected and managed. Through the Juan Healthy Lung Program, we are focusing on early detection, better patient support and preventing complications so that patients live longer, healthier lives." Home to more than three million residents, Quezon City continues to invest in programs that strengthen access to healthcare services at the community level. "Every healthy community is built not only by treating disease, but by preventing it," said Joy Belmonte, Quezon City Mayor. "When we help one person breathe easier, provide for their family, and live a healthier life, the benefits extend far beyond the individual. They strengthen the entire community." Mayor Joy Belmonte, along with AstraZeneca Philippines Country President Lotis Ramin, signed an MOA expressing their joint commitment to improving lung health outcomes for QC residents. A public-private response. COPD is a chronic, progressive disease that narrows the airways and damages lung tissue, making it increasingly harder to breathe over time. In the Philippines, smoking remains the leading driver with approximately 16.3 million smokers nationwide, though exposure to air pollutants, biomass fuel, and occupational hazards also contributes significantly. The risk is particularly pronounced in urban areas: studies indicate COPD prevalence among smokers in Metro Manila reaches 40%, compared to 28% in rural communities, yet many receive a diagnosis only after the disease has already advanced, limiting the window for early intervention and delaying appropriate care. The Juan Healthy Lung COPD Screening Program brings together AstraZeneca's expertise in respiratory health and the Quezon City Government's extensive community health infrastructure to address COPD at the grassroots level. The program will deliver COPD risk assessments and screenings, training for healthcare workers on early identification, patient and community awareness campaigns and the development of referral pathways to connect at-risk individuals with proper treatment. "Many patients remain undiagnosed until symptoms have already progressed, limiting opportunities for early intervention and appropriate care," said Dr. Cyril Tolosa, Medical Affairs Director, AstraZeneca Philippines. "By bringing screening, education, and support closer to where people live, this initiative aims to help more QCitizens access timely care, improve health outcomes, and take an important step toward building healthier and more resilient communities."AstraZeneca Medical Affairs Director, Dr. Cyril Tolosa, said the Juan Healthy Lung COPD Screening Program will bring early detection and timely care to the residents of Quezon City. As the program rolls out, the Quezon City Government and AstraZeneca will monitor reach and outcomes to strengthen community-based lung health efforts over time. Quezon City residents are encouraged to stay updated through official channels for information on COPD awareness activities, screening opportunities, and program updates under the Juan Healthy Lung Program. Related topics. 8List.ph is a groundbreaking and award-winning site that provides your daily dose of entertaining, useful and informative lists.
Abstract: Evaluating automatic detection of incompatibility between male mice for timely intervention using TrackPaw. A collaboration between TrackPaw and AstraZeneca. 1: Animal Science and Technology, Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden 2: TrackPaw Scientific AB, Lund, Sweden Group housed male mice can develop aggressive behaviour as social hierarchies form. When dominance and submission do not stabilise, fighting may escalate, compromising both animal welfare and data quality. Currently, incompatibility is identified through daytime manual checks, which may detect issues only after overt signs, such as visible fighting wounds have appeared. Because this method does not provide continuous monitoring during the mice's peak activity periods, aggressive altercations can be missed between inspections, increasing the risk of preventable harm. To find means for more predictive and targeted interventions, TrackPaw Scientific AB, in collaboration with AstraZeneca, is developing an automated home cage monitoring platform for group housed male mice. TrackPaw is a weight sensor and RFID based system that replaces the standard cage in the rack and continuously tracks weight and movement of microchipped mice. Using these data, the system detects high intensity events (HIE) indicative of ongoing aggressive behaviour and alerts users when predefined thresholds are exceeded. To assess how HIE alerts can be used for practical colony management, 30 C57/Bl6 male mice (4 weeks old) were monitored in groups of three over 56 days using TrackPaw. Building on a previous study of 21 C57 male mice, where camera surveillance served as ground truth and false alarms were rare, this study aimed to define an alert threshold that would enable separation prior to incompatibility activities reaching their peak and before visible damage occurs. An optimal threshold of HIE was set at 180 seconds of detected activity within each 24-hour window (6 PM to 6 PM), and TrackPaw alerts enabled timely, targeted interventions in the relevant cages. The next step is to identify how climbing ties into the story, how RFID could be used to identify potential aggressors, and to compare similar baseline measurements for females of the same age, to streamline the process of separation and improve animal welfare.